Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499428 | 0.87 | KMT2A (0.46) | MAPK1TSHRKMT2AHPGDALDH1A1 | |
| SCHEMBL3143722 | 0.86 | MAPK1 (0.39) | MAPK1TSHRKMT2AHPGDFAAH | |
| SCHEMBL12018040 | 0.85 | CYP19A1 (0.40) | MAPK1TSHRLMNAKMT2AHPGD | |
| SCHEMBL22106618 | 0.84 | PTGS1 (0.41) | PTGS1PTGS2CXCR1CXCR2TSHR | |
| SCHEMBL4079296 | 0.83 | MAPK1 (0.39) | MAPK1TSHRLMNAKMT2AHPGD | |
| SCHEMBL15896085 | 0.83 | KMT2A (0.44) | MAPK1KMT2AHPGDMEN1NPC1 | |
| SCHEMBL17356716 | 0.83 | KMT2A (0.41) | MAPK1LMNAKMT2AHPGDALDH1A1 | |
| SCHEMBL4082771 | 0.81 | MAPK1 (0.39) | MAPK1TSHRKMT2AHPGDFAAH | |
| SCHEMBL10085431 | 0.81 | PTGS2 (0.53) | PTGS1PTGS2CXCR1CXCR2TSHR | |
| SCHEMBL4083706 | 0.81 | MAPK1 (0.37) | MAPK1TSHRKMT2AHPGDFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240207423-A1 | PROGAMMABLE POLYMERIC DRUGS | SONY GROUP CORP (JP) | 2024-06-27 | — | — | US | disclosed |
| US-20210128739-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20200360526-A1 | PHOSPHOALKYL POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | Sony Group Corporation (JP) | 2020-11-19 | — | — | US | disclosed |
| US-20200353094-A1 | PHOSPHOALKYL RIBOSE POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | Sony Group Corporation (JP) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128739-A1 | PROGRAMMABLE POLYMERIC DRUGS | CHRM1, PBRM1, MRPL21 | MAPK1 3378/4885PTGS1 2224/4885PTGS2 3654/4885 |
| US-20200353094-A1 | PHOSPHOALKYL RIBOSE POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | PARP1, PARP11, PHOSPHO1 | MAPK1 1914/4885PTGS1 3406/4885PTGS2 4298/4885 |
| US-20200360526-A1 | PHOSPHOALKYL POLYMERS COMPRISING BIOLOGICALLY ACTIVE COMPOUNDS | PHOSPHO1, PGM2, PHYKPL | MAPK1 668/4885PTGS1 2289/4885PTGS2 3709/4885 |
| US-20240207423-A1 | PROGAMMABLE POLYMERIC DRUGS | OPRM1, CHRM1, TUBB3 | MAPK1 2712/4885PTGS1 668/4885PTGS2 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.